Kisqali OverviewRibociclib (trade name Kisqali) is an inhibitor of cyclin D1/CDK4 and CDK6, and is used for the treatment of certain kinds of breast cancer. It is also being studied as a treatment for other drug-resistant cancers. It was developed by Novartis and Astex Pharmaceuticals. Contents 1 Medical uses 2 Side effects 3 Interactions 4 Pharmacology 4.1 Mechanism of action 4.2 Pharmacokinetics 5 Research 6 Chemistry 7 See ...
Read more Kisqali Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Ribociclib
Recent Kisqali Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Tablet: 200mg
NDC Database Records for Kisqali: (3 results)Sorted by National Drug Code
- 0078-0860 Kisqali 200 mg Oral Tablet, Film Coated by Novartis Pharmaceuticals Corporation
- 0078-0867 Kisqali 200 mg Oral Tablet, Film Coated by Novartis Pharmaceuticals Corporation
- 0078-0874 Kisqali 200 mg Oral Tablet, Film Coated by Novartis Pharmaceuticals Corporation